1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends

Growth Drivers for Biomarkers in Healthcare : Managing Success in the Biomarker Industry - Challenges and Opportunities

  • March 2015
  • 73 pages
  • Frost & Sullivan
Report ID: 2779405

Summary

Table of Contents

Key Findings

•The global biomarkers market was estimated at $ x billion in 2014 and is expected to reach $ x billion in 2020, growing at a robust CAGR of x % (2014–2020).
•North America is the highest revenue-generating region with $ x billion revenue in 2014, accounting for x % of the total global biomarkers market.
•Genomics is the highest revenue-generating segment with a revenue of $ x billion in 2014, accounting for x % of the total global biomarkers market. The segment is expected to grow at a CAGR of x % (2014–2020).
•The Asia-Pacific region will experience the highest growth rate in the forecast period, outpacing other regions, with a CAGR of x % (2014–2020).
•Currently, the adoption of genomics- and proteomics-based biomarkers is the highest, with a number of novel lipidomics and immunomics markers coming to the fore.
•Developments in the ‘omics’ platforms, such as glycomics, lipidomics, and immunomics, are paving way for the discovery of potentially useful biomarkers that can be used for early diagnosis, prognosis, and drug development.
•Complex diseases with unmet needs are the major areas for biomarker development. Traumatic brain injury (TBI), cardiovascular diseases (CVDs), and autoimmune diseases are some of the areas witnessing quality R&D* of novel biomarker-based tests.
•With the advent of personalised medicine and more patient-based care, there has been an increased activity in the partnerships between pharmaceutical companies and in-vitro diagnostic (IVD) companies.
•A majority of genetic tests are yet to be recognised by the reimbursement system. Once the value of biomarker assays is established, the reimbursement policies linked to them are likely to change.
•Oncology is an area with the highest number of initiatives and funding for biomarker research—a key opportunity for companies and organisations working in this space.
•Quick translation of biomarker-based diagnostics is being made possible with biomarker qualification strategies and the establishment of biomarker validation companies that focus on cancer and CVD biomarkers.

Biomarker in R&D
A majority of pharmaceutical companies are hesitant in using biomarkers in R&D, mainly due to the belief that it could narrow down the commercial aspect of a drug.
Biomarkers will become an integral part of R&D processes. Pharmaceutical companies have started realising the importance of personalised medicine in serving even small addressable segments with commercial benefits.

Patient treatment and diagnostic model
It is ‘one-drug-one-diagnostic’ model.
It will move towards ‘one-patient-multibiomarker-and-multifactorial’ diagnostic model. This will provide a holistic approach to patients and physicians in choosing optimal treatment options.

‘Omics’ technologies
Analysis of nucleic acids using biomarkers is the most developed clinical application. Oncology applications and genomic analysis are the most common among them.
Genomics is expected to dominate. As Genomics technologies become more common, prices of genomic biomarkers and whole-gene sequencing are expected to fall. However, other ‘omics’ technologies in drug discovery, such as transcriptomics, epigenomics, proteomics, metabolomics, and lipidomics, are expected to grow.

New Market Opportunities

Standardisation of validation protocols for biomarkers is not well established; biomarkers often face commercial and regulatory problems.
Collecting adequate samples for data analysis can be achieved by:
•Companies need to start sharing data and information to validate biomarkers extensively.
•Sample integrity by clinical development companies will ensure high quality of sample.
•Application of advanced technologies such as Big Data can be instrumental in better understanding and validation of biomarkers.

Strategies for the use of biomarkers in clinical trials are unclear.
•Deciding the use and role of a potential biomarker at an early stage of clinical trial can impact the success of a biomarker.
•Adaptive trial design and Bayesian statistical approaches with computational modelling and simulation using biomarkers will help in getting efficient and timely clinical trial results.

There is a need for a collaborative model that will enable companies to self-finance the demonstration of clinical utility and bring products to market on time.
•Collaboration with pharmaceutical companies will help diagnostic companies in the linkage between companion tests and specific drugs, which may facilitate regulatory approval and uptake in clinical settings.
•Incorporation of single biomarkers into simple molecular and non-molecular tests; the use of existing technology platforms by well-established diagnostic companies may enable the provision of low-cost tests.

Key Innovations and Companies to Watch

Google: Launched a massive scientific study to detect illness biomarkers

•The company has started a huge project to establish the genetic and molecular profile of a perfectly healthy human body.
•The project will help researchers and physicians to detect specific biomarkers buried in the information and use these biomarkers to detect diseases at a very early stage.
•Google aims to use its computational power to find these biomarkers.

Qiagen: Launched a cancer biomarker analysis project with Eli Lilly
•Qiagen and Lilly have entered into a contract to co-develop companion diagnostics that can handle simultaneous analysis of DNA and RNA biomarkers for various types of cancer.
•Qiagen will leverage its FDA-approved proprietary technology known as Modaplex analysis platform. The platform is capable of handling multiple samples and biomarkers in a single test.
•Eli Lilly’s aim is to broaden its personalised healthcare portfolio.

Biocartis: Launched its flagship molecular diagnostics platform Idylla
•Idylla is a fully automated, real-time PCR-based molecular system.
•It is capable of rapidly detecting biomarkers in cancer samples with a high sensitivity when compared to other standard diagnostic assays and sequencing.
•The company is working on developing specialised assays that will allow clinicians to detect more that 30 biomarkers per sample.

Quanterix: Announced the Simoa Accelerator launch
•Quaterix announced the launch of Simoa Accelerator in December 2014.
•It is an innovation centre for biomarker research and custom assay development.
•Simoa Accelerator will help scientists and clinicians to explore biomarkers with greater precision and sensitivity.
•This will help in the development of improved diagnostic tests and management of diseases such as cancer and neurological disorders.

Protagen AG: Developed its proprietary platform, SeroTag
•Protagen AG has developed its innovative proprietary platform, SeroTag, which can be used for biomarker discovery.
•This helps in the identification of autoantibody signatures in blood, which will help in the development of IVD, patient stratification, and therapy selection.
•Protagen has signed agreements with Qiagen to develop novel protein-based companion diagnostics for autoimmune therapies.

Indivumed GmbH: Developed a unique protein biomarker discovery strategy
•Indivumed GmbH has developed a unique strategy for protein biomarker discovery.
•It is a combination of cellular specificity and selectivity of laser-capture microdissection (LCM) and the sensitivity of liquid chromatography coupled with mass spectrometry (LC-MALDI MS).
•Indivumed holds an advantage in terms of availability of a highly characterised bio-bank that offers the possibility of selecting tissues for biomarker discovery.

BioSystems: Is developing an innovative series of antibody microarrays
•BioSystems is involved in protein biomarker R&D as well as biomarker discovery through an innovative process called Monoclonal Antibody Proteomics.
•The company is developing an innovative series of antibody microarrays, PlasmaScan and QuantiPlasma, in collaboration with Arrayit Corporation and Randox Laboratories.
•These microarrays will serve as powerful discovery tools for blood-based diagnostics by facilitating the discovery of blood-based biomarkers.

Thermo Fisher Scientific: Launched Thermo Scientific Dionex GlycanPac AXH-1 HPLC
•Glycans are being researched as potential biomarkers. In February 2013, Thermo Fisher Scientific introduced the Thermo Scientific Dionex GlycanPac AXH-1 HPLC column for the separation of glycans based on charge, size, and polarity.
•The new workflow in metabolomics research can enhance glycan analysis.
•The company renewed its long-term, royalty-bearing agreement with Roche for improved detection of sepsis using a Procalcitonin (PCT) biomarker.

Roche: Is developing a Lampalizumab biomarker for geographic atrophy (GA)
•Roche is developing a Lampalizumab biomarker for geographic atrophy (GA), an advanced form of dry age-related macular degeneration. It is in phase II clinical trial stage.
•The company is also developing a prognostic marker for Alzheimer’s, and a biomarker is under evaluation for Schizophrenia.
•In July 2013, Roche renewed its partnership with Thermo Fisher Scientific for improved detection of sepsis using a PCT biomarker.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Cancer Biomarkers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • $ 5795
  • Industry report
  • May 2017
  • by Transparency Market Research

Global Cancer Biomarkers Market: Overview Biomarkers are the substance or molecules found in blood, other body fluids or tissues which states the normal and abnormal condition of the body, biomarkers ...

Next-Generation Sequencing (NGS) Market by Product (Hiseq, Miseq, Hiseq X Ten/X Five, NextSeq500, Ion Proton, PGM, Ions5, PacBio RSII), Services (Targeted, RNA, Exome, De Novo), & Application (Diagnostics, Biomarker, Agriculture) - Global Forecasts to 202

  • $ 5650
  • Industry report
  • April 2017
  • by MarketsandMarkets

The global next-generation sequencing market is estimated to register a CAGR of 20.5% from 2017 to 2022 to reach USD 12.45 billion by 2022. Factors such as technological advancements in NGS platforms, ...

Biomarkers Enabling Diabetes and Obesity Management

  • $ 4950
  • Industry report
  • March 2017
  • by Frost & Sullivan

Novel Biomarker Research is Likely to Transform the Future of Obesity and Diabetes Management Obesity and diabetes are areas of growing concern across both, developed and developing countries. The rising ...


Download Unlimited Documents from Trusted Public Sources

Genomics Industry in the US

  • June 2017
    63 pages
  • Genomics  

  • United States  

    North America  

View report >

Health Care Provider Industry in the US - Forecast

  • May 2017
    9 pages
  • Health Care Pro...  

    Lung Cancer  

    Cancer  

  • United States  

    North America  

View report >

Genomics Industry in Denmark

  • May 2017
    7 pages
  • Genomics  

  • Denmark  

View report >

Related Market Segments :

Biomarker

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.